 Cardiff Oncology Inc NASDAQ: CRDF has announced data from its ongoing Phase 1b2 trial evaluating onvansertib combined with standard-of-care therapy in second-line KRAS-mutated metastatic colorectal cancer mCRC. Patients enrolled in the trial receive onvansertib combined with standard-of-care Folfiri Chemo and Roche Holdings AGs OTC: RHHBY Avastin bevacizumab. 